San Francisco—While state-of-the-art combination antiretroviral therapy has had an enormous impact in extending and improving the lives of patients with HIV infection, clinicians are increasingly faced with the question of how to help patients who fail to respond to standard anti-HIV drugs because of emerging resistance or other factors. One strategy being pursued by researchers, with the hope of buying time for such patients, is the development of a class of drugs called fusion inhibitors.
Stephenson J. New Class of Anti-HIV Drugs. JAMA. 1999;282(21):1994. doi:10.1001/jama.282.21.1994-JMN1201-3-1